73 related articles for article (PubMed ID: 36573552)
1. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
[TBL] [Abstract][Full Text] [Related]
2. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation.
Mo S; Ye L; Wang D; Han L; Zhou S; Wang H; Dai W; Wang Y; Luo W; Wang R; Xu Y; Cai S; Liu R; Wang Z; Cai G
JAMA Oncol; 2023 Jun; 9(6):770-778. PubMed ID: 37079312
[TBL] [Abstract][Full Text] [Related]
3. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population: a prospective cohort study.
Zhao F; Bai P; Xu J; Li Z; Muhammad S; Li D; Zhang Z; Gao Y; Liu Q
Mol Cancer; 2023 Sep; 22(1):157. PubMed ID: 37770864
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.
Symonds EL; Pedersen SK; Murray DH; Jedi M; Byrne SE; Rabbitt P; Baker RT; Bastin D; Young GP
Clin Epigenetics; 2018; 10():63. PubMed ID: 29796114
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profile in CpG-depleted regions uncovers a high-risk subtype of early-stage colorectal cancer.
Yu H; Wang X; Bai L; Tang G; Carter KT; Cui J; Huang P; Liang L; Ding Y; Cai M; Huang M; Liu H; Cao G; Gallinger S; Pai RK; Buchanan DD; Win AK; Newcomb PA; Wang J; Grady WM; Luo Y
J Natl Cancer Inst; 2023 Jan; 115(1):52-61. PubMed ID: 36171645
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide and panel-based cell-free DNA characterization of patients with resectable esophageal adenocarcinoma.
van den Ende T; van der Pol Y; Creemers A; Moldovan N; Boers D; van Berge Henegouwen MI; Hulshof MC; Cillessen SA; van Grieken NC; Pegtel DM; Derks S; Bijlsma MF; Mouliere F; van Laarhoven HW
J Pathol; 2023 Nov; 261(3):286-297. PubMed ID: 37615198
[TBL] [Abstract][Full Text] [Related]
8. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
[TBL] [Abstract][Full Text] [Related]
9. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.
Yuan SQ; Nie RC; Huang YS; Chen YB; Wang SY; Sun XW; Li YF; Liu ZK; Chen YX; Yao YC; Xu Y; Qiu HB; Liang Y; Wang W; Liu ZX; Zhao Q; Xu RH; Zhou ZW; Wang F
Cancer Commun (Lond); 2023 Dec; 43(12):1312-1325. PubMed ID: 37837629
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer.
Emiloju OE; Storandt M; Zemla T; Tran N; Jethwa K; Mahipal A; Mitchell J; Thiels C; Mathis K; McWilliams R; Hubbard J; Sinicrope F; Shi Q; Jin Z
JCO Precis Oncol; 2024 Jan; 8():e2300127. PubMed ID: 38237099
[TBL] [Abstract][Full Text] [Related]
11. Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles.
Yasui K; Toshima T; Inada R; Umeda Y; Yano S; Tanioka H; Nyuya A; Fujiwara T; Yamada T; Naomoto Y; Goel A; Nagasaka T
Mol Cancer; 2024 Jan; 23(1):1. PubMed ID: 38172877
[TBL] [Abstract][Full Text] [Related]
12. Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.
Nakano T; Takao S; Dairaku K; Uno N; Low SA; Hashimoto M; Tsuda Y; Hisamatsu Y; Toshima T; Yonemura Y; Masuda T; Eto K; Ikegami T; Fukunaga Y; Niida A; Nagayama S; Mimori K
Cancer Sci; 2024 Jun; 115(6):1989-2001. PubMed ID: 38531808
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide methylation profiling identifies a novel gene signature for patients with synchronous colorectal cancer.
Okada Y; Peng F; Perea J; Corchete L; Bujanda L; Li W; Goel A
Br J Cancer; 2023 Jan; 128(1):112-120. PubMed ID: 36319845
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
[TBL] [Abstract][Full Text] [Related]
15. Value of ctDNA methylation biomarkers in diagnosis of colorectal tumors.
Shi YJ; Dong YH; Mei ZB; Wang H
Epigenomics; 2023 Sep; 15(18):891-893. PubMed ID: 37846515
[TBL] [Abstract][Full Text] [Related]
16. A sensitive and robust plasma-based DNA methylation panel for early detection of target gastrointestinal cancers.
Dai Y; Li H; Wu Q; Wang J; Wang K; Fei S; Pei B; Song L; Chen G; Ma Y; Xia C; Xiong S; Zheng M; Xue Y; Zhao G; Xu H
Neoplasia; 2023 Dec; 46():100941. PubMed ID: 37918207
[TBL] [Abstract][Full Text] [Related]
17. External quality assessment for detection of colorectal cancer by Septin9 DNA methylation in clinical laboratories.
Chang L; Wang D; Han Y; Diao Z; Chen Y; Li J; Zhang R
Clin Chim Acta; 2024 Jan; 552():117663. PubMed ID: 38008152
[TBL] [Abstract][Full Text] [Related]
18. Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges.
Wen X; Coradduzza D; Shen J; Scanu AM; Muroni MR; Massidda M; Rallo V; Carru C; Angius A; De Miglio MR
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893604
[TBL] [Abstract][Full Text] [Related]
19. DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer.
Xie Y; Li P; Sun D; Qi Q; Ma S; Zhao Y; Zhang S; Wang T; Wang J; Li S; Gong T; Xu H; Xiong M; Li G; You C; Luo Z; Li J; Wang C; Du L
Cancer Res; 2023 Nov; 83(21):3636-3649. PubMed ID: 37602818
[TBL] [Abstract][Full Text] [Related]
20. Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies.
Zhu M; Taylor WR; Mahoney DW; Then SS; Berger CK; Burger KN; Gonser AM; Doering KA; Xie H; Foote PH; Kaiser MW; Allawi HT; Hubbard JM; Kisiel JB
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
